NMD Pharma

NMD Pharma is testing its lead drug candidate, NMD670, in a Phase I/IIa clinical trial for Myasthenia Gravis at the Centre for Human Drug Research in Leiden, led by Dr. Geert Jan Groeneveld.

Skeletal muscles, making up 40% of body mass, enable essential functions like breathing and walking. Their activity is controlled by the nervous system at specialized membrane areas.

NMD Pharma develops small-molecule inhibitors targeting skeletal muscle-specific ClC-1 chloride ion channels for orphan diseases and other indications.

NMD Pharma develops small-molecule inhibitors targeting skeletal muscle-specific ClC-1 ion channels for orphan diseases and clinical indications.

Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition

New publication identifies neuromuscular junction transmission failure as a novel mechanism contributing to sarcopenia, with preclinical studies showing that ClC-1 inhibition improves neuromuscular transmission and muscle function NMD Pharma is advancing a multi-asset ClC-1 portfolio targeting

NMD Pharma’s CEO Thomas Holm Pedersen and COO Thomas Kongstad Petersen met with Danish Chamber of Commerce leaders to discuss biotech and life science expansion.

Nordic Life Science News interviewed Anders Findsen, a Research Scientist at NMD Pharma, in its latest edition.

Mike joined NMD Pharma as Chairman in December 2022, bringing 30 years of experience in biopharmaceutical development and commercialization. He previously founded Avenge Bio, where he serves as Chairman and CEO, and Collegium Pharmaceutical, where he was CEO until 2018 and remains Chairman.

Ole studies the regulation of channels and transporters in skeletal muscles, focusing on muscle excitability and function. He has published over 70 papers, including work on integrated physiology, and became a professor at Aarhus University in 2008, where his research influenced NMD Pharma’s activities.

I am Kamilla Løhde Dybdahl, a Research Scientist and part of the Team Screening research team at NMD Pharma. As part of my day-to-day role, I perform ex vivo experiments in electrophysiology, mainly drug screening, but also smaller key research projects. The rest of my time is spent on data analysis and writing reports or preparing presentations. I am also a member of the EHS (environmental health and safety) group.

Thomas co-founded NMD Pharma in 2015 and has served as CEO, leading the company from discovery-stage to clinical-stage. He oversaw financing rounds, including a large Series A investment in Europe in 2018.

NMD Pharma develops small-molecule therapies targeting skeletal muscle to treat rare neuromuscular diseases and age-related conditions with unmet medical needs.

A future in which patients with neuromuscular disease live better and more independent lives.

Denmark NMD Pharma A/S Palle Juul-Jensens Boulevard 82 8200 Aarhus N

NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases.

NMD Pharma processes personal data as the data controller, outlining purposes and legal bases for handling.

This website is owned by NMD Pharma A/S, Palle Juul-Jensens Boulevard 82, 8200 Aarhus N, Denmark.